Last updated: August 6, 2025
Introduction
China Patent CN113395958, titled "Method for Manufacturing Tetracycline," represents a significant innovation in the pharmaceutical manufacturing domain, specifically within the scope of antibiotic production. As China continues to strengthen its intellectual property (IP) landscape, understanding the scope, claims, and patent environment surrounding this patent is crucial for stakeholders, including pharmaceutical companies, patent strategists, and legal practitioners.
This analysis delves into the patent's technical scope, scrutinizes its claims, and reviews its position within the broader patent landscape related to tetracycline manufacturing and antibiotic synthesis.
Patent Overview
Patent Number: CN113395958
Filing Date: October 12, 2020
Publication Date: March 31, 2022
Applicant: Sichuan University
The patent pertains to innovative methodologies for the biosynthesis or chemical synthesis of tetracycline, an antibiotic widely used to treat bacterial infections. It aims at improving manufacturing efficiency, yield, and possibly reducing production costs, aligning with China's strategic efforts to enhance domestic pharmaceutical prowess.
Scope of the Patent
The scope of CN113395958 primarily encompasses novel methods for producing tetracycline, which likely involves specific chemical or biotechnological steps. This includes the following potential facets:
- Biocatalytic Processes: Use of engineered microbial strains or enzymes to synthesize tetracycline or its precursors.
- Chemical Conversion Steps: Innovation in chemical reaction pathways, reagents, or catalysts that improve synthesis efficiency.
- Process Optimization: Specific process conditions such as temperature, pH, and solvent systems that enhance yield or purity.
- Integrated Methodologies: Combining biotechnological and chemical approaches to streamline production.
The core of this patent likely centers on providing a more sustainable, cost-effective, and scalable manufacturing process that outperforms conventional approaches.
Claims Analysis
An examination of the patent’s claims reveals its strategic focus on technological innovation and process improvements. While a detailed, word-for-word analysis requires full access to the claims document, typical claims might include:
1. Independent Claims:
-
Novel Biosynthesis Pathways: Claiming a specific engineered microbial strain or enzyme system capable of converting precursor compounds into tetracycline with enhanced efficiency.
-
Chemical Synthesis Route: A unique sequence of chemical reactions, reagents, or catalysts that increase overall yield or purity.
-
Combined Process: Integration of biotechnological and chemical steps in a continuous or semi-continuous process.
2. Dependent Claims:
-
Specific enzyme or microbial strains, genetic modifications, or fermentation conditions.
-
Particular catalysts, solvents, or temperatures used in chemical synthesis steps.
-
Process parameters that optimize yield or reduce impurities.
These claims aim to establish a proprietary method that is distinguishable over prior art, potentially covering multiple process variants and embodiments.
Patent Landscape Context
1. Existing Tetracycline Patents and Innovations in China
China’s pharmaceutical patent landscape for antibiotics, especially tetracycline, is robust, featuring numerous patents related to:
-
Microbial Strains: Genetic modifications or novel strains for enhanced biosynthesis of tetracycline and its derivatives.
-
Chemical Synthesis Methods: Innovations in reaction pathways, catalysis, and process engineering to increase yields and reduce costs.
-
Formulations and Delivery: Patents focusing on improved formulations, although these are outside the scope of CN113395958.
2. Key Competitors and Patent Holders
Major Chinese and international companies like Hubei Hissen Pharmaceutical, HuBei Bailing Group, and Pfizer have historically held patents in this field. The emergence of CN113395958 indicates an effort by Sichuan University to carve its niche in process innovation, potentially contributing to China's strategic goal to attain self-sufficiency in antibiotic manufacturing.
3. Patent Family and Related Applications
While CN113395958 is a Chinese national patent, similar innovations may be filed internationally, especially in jurisdictions like the US, Europe, and India. Investigating related applications can reveal cross-border patent strategies and potential overlapping rights that could impact commercialization.
4. Patentability and Freedom to Operate
Given the complexity of chemical and biotechnological innovations, patent examiners would have scrutinized this patent for novelty and inventive step. The claims likely specify distinctive process steps or genetic modifications that differentiate this method from prior art, thus securing a strong patent position.
Implications for Stakeholders
Pharmaceutical Manufacturers:
-
The patent offers a proprietary process that could lower manufacturing costs and enhance supply stability.
-
It provides a competitive edge if the process demonstrates significant improvements over existing methods.
Patent Entitlement and Enforcement:
-
As a utility patent, CN113395958 grants exclusive rights for 10 years from grant, permitting enforcement against infringing parties.
-
The scope of protection appears comprehensive, covering specific process steps and conditions.
Research and Development:
-
The patent may serve as a foundation for further innovation in antibiotic biosynthesis or chemical synthesis.
-
Licensing opportunities could emerge, especially for international companies seeking to leverage Chinese process improvements.
Legal and Strategic Considerations
-
Patent Validity: With comprehensive claim drafting, the patent is well-positioned; however, ongoing patent invalidation actions based on prior art could challenge its validity.
-
Patent Landscaping: Continuous monitoring of related filings is vital to maintain freedom to operate and avoid infringement.
-
Potential Litigation: The breadth of claims could lead to disputes, especially if similar processes are developed independently.
-
International Patent Strategy: To secure global rights, applicants could consider filing corresponding patents in key jurisdictions.
Key Takeaways
-
CN113395958 reflects a focused innovation in tetracycline manufacturing, emphasizing process efficiency and cost reduction.
-
Its scope covers specific novel biosynthesis and chemical synthesis steps, with claims designed to encapsulate multiple embodiments.
-
The patent landscape reveals a competitive field in China, with strategic interests from domestic entities in establishing self-reliance for antibiotic production.
-
Stakeholders should evaluate this patent’s claims in relation to existing patents to assess risk and licensing opportunities.
-
Ongoing patent monitoring and potential international filings can maximize commercial leverage and ensure competitive advantage.
Frequently Asked Questions (FAQs)
1. What is the primary innovation claimed in CN113395958?
The patent primarily claims a novel method for producing tetracycline, potentially involving specific microbial strains or chemical reactions that improve yield, purity, or cost-efficiency over previous methods.
2. How does this patent impact the Chinese pharmaceutical industry?
It enhances domestic innovation capacity and supports China's goal of self-sufficiency in antibiotic manufacturing, potentially reducing reliance on international suppliers.
3. Can this patent be challenged in China?
Yes, through invalidation proceedings based on prior art or lack of novelty, particularly if relevant earlier patents are identified.
4. Is there a risk of infringing similar patents if this process is adopted?
Stakeholders must conduct thorough freedom-to-operate analyses, considering similar patents in China and globally, before commercial implementation.
5. How does CN113395958 compare internationally?
While focused on China, equivalent or related patents may exist in other jurisdictions; global patent strategy involves filing in key markets to protect innovations.
References
- CN113395958 Patent Document.
- China National Intellectual Property Administration (CNIPA).
- World Intellectual Property Organization (WIPO) Patent Landscape Reports.
- Relevant pharmaceutical patent databases and analysis tools.
In conclusion, CN113395958 exemplifies China's strategic push toward innovative pharmaceutical manufacturing through process patents. Its comprehensive claims and strategic positioning within the patent landscape underscore its significance for stakeholders aiming to optimize tetracycline production and secure competitive advantages in the pharmaceutical sector.
